Recent Articles in Cell & Gene Therapy

Sirnaomics, a Suzhou-Maryland RNAi company, has dosed the first patient in a Phase I clinical study of its lead siRNA (small interfering RNA) candidate as a fat reduction agent in adults undergoing abdominoplasty. STP705 is already being tested as a therapy for cholangiocarcinoma, non-melanoma skin cancer and hypertrophic scar. Sirnaomics said the dose setting trial will examine STP705 for its fat reduction and subcutaneous tissue remodeling effects, pointing out that existing therapies require multiple sessions to produce only mild effects. More details....

Stock Symbol: (HK: 2257)

Share this with colleagues:  

Insilico Medicine, a Hong Kong-New York City AI drug discovery company, signed a six-drug research collaboration with Sanofi that could be worth up to $1.2 billion. Insilico will receive up to $21.5 million in upfront and target nomination fees for each of the six targets. It will also be eligible for milestone and royalty payments. Insilico will apply its end-to-end Pharma.AI platform to the Sanofi targets, including interdisciplinary drug discovery scientists who will advance lead therapeutic compounds up to candidate development stage. More details....

Share this with colleagues:  

Shanghai XellSmart Biomedical closed a $27.6 million in Series A1 financing to develop low-cost stem cell therapies for major unmet needs including Parkinson's disease. Founded in 2021, XellSmart has a 1,400-square-meter Shanghai R&D center and a 3,400-square-meter pilot production base in Suzhou under construction. Besides Parkingson’s, the company is developing stem cell therapies for retinopathy, brain trauma and cancer. The round was co-led by Qiming Venture, Lilly Asia Ventures, FIG and CSSD. Qiming and Lilly are previous investors. More details....

Share this with colleagues:  

Wuhan Neurophth announced a $140 million agreement to use Cyagen’s AI platform to discover novel AAV vectors. Cyagen is a Santa Clara, CA gene therapy CRO with offices in China and Japan that offers genetically modified rodent models. Neurophth is developing gene therapies for ophthalmology indications. The company’s lead drug recently started a Phase III trial for ND4-mediated Leber's hereditary optic neuropathy (ND4-LHON) with plans to conduct trials of the drug in China and the US. More details....

Share this with colleagues:  

Beijing Immunochina raised at least $28 million in a Series D+ round of to support the NDA filing and commercialization of its lead product, CAR-T IM19. The IM19 molecule, a CD19 CAR-T immunotherapy, was tested in patients with B-Cell Acute Lymphoblastic Leukemia and Non Hodgkin’s Lymphoma. Simcere partners the drug. The company's portfolio includes ten CAR-T assets. Immunochina’s latest financing was co-invested by Beijing Zhongguancun Science City Innovation Development and BCT Capital. More details....

Share this with colleagues: